RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I
trial to study the effectiveness of stereotactic radiosurgery in treating patients who have
OBJECTIVES: I. Establish stereotaxic radiosurgery as a treatment technique at the National
Institute of Health in patients with intracranial neoplasms.
II. Assess the response rate, local control, time to progression, pattern of failure, and
magnetic resonance spectrographic data following this therapy in these patients.
PROTOCOL OUTLINE: All patients undergo stereotaxic head frame placement, followed by
stereotaxic radiosurgery on day 1. The dosage of radiation therapy administered is dependent
on the tumor diameter.
Patients are followed at 2 and 6 weeks and then every 3 months for 5 years.
Up to 30 patients will be accrued for this study within 7-10 months.
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Histologically proven intracranial tumor OR Pathologically
confirmed cancer with metastases to the brain OR Newly discovered brain lesions that are
amenable to stereotaxic biopsy No more than 3 measurable tumors Only 1 tumor more than 3
cm in diameter that requires radiosurgery allowed No tumor more than 4 cm in diameter No
tumor that involves more than 50% of the brain stem --Prior/Concurrent Therapy-- Biologic
therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Concurrent
corticosteroids allowed Radiotherapy: Prior cranial radiotherapy allowed Surgery:
Radiosurgery to other nonstudy intracranial lesions allowed Prior biopsy and/or subtotal
or near-total resection allowed --Patient Characteristics-- Age: 18 and over Performance
status: Karnofsky 70-100% OR ECOG 0-2 Life expectancy: More than 3 months Hematopoietic:
WBC at least 3,000/mm3 Absolute granulocyte count at least 500/mm3 Hemoglobin at least 10
g/dL Platelet count at least 50,000/mm3 Hepatic: SGOT or SGPT no greater than 2.5 times
upper limit of normal (ULN) PT and PTT no greater than 1.5 times ULN No clinically
significant hepatic dysfunction Renal: Creatinine no greater than 1.3 times ULN
Cardiovascular: No clinically significant cardiac dysfunction Pulmonary: No clinically
significant pulmonary dysfunction Other: Not pregnant or nursing Negative pregnancy test
No clinically significant systemic illness or serious infection that would preclude study
compliance No other organ dysfunction that would preclude study compliance No history of
psychiatric disease No allergy to contrast agent Papilledema and motor or sensory deficits
allowed No contraindications to MRI (e.g., aneurysm clip, implanted neural stimulator,
implanted cardiac defibrillator, cochlear implant, ocular foreign body or implant, or